Ceres Nanosciences, Inc., a Manassas, Virginia-based biotechnology company, raised $3m in Series A financing.
The funding, part of a larger $9m round, was led by GreyBird Ventures, which is committing up to $5.5MM over the next year. In conjunction with the funding, Tom Miller, a co-founder of GreyBird Ventures, has joined Ceres’ board.
Led by CEO Ross Dunlap, Ceres has developed and commercialized a novel nanoparticle technology, the Nanotrap®, which provides biomarker capture and biofluid sample processing capabilities for a wide array of diagnostic applications and sample handling needs.
The technology was invented at George Mason University and developed under funding from the National Institutes of Health (NIH) for biomarker discovery applications. With support from the NIH, the Defense Advanced Research Projects Agency (DARPA), the Bill and Melinda Gates Foundation, and the Commonwealth of Virginia, Ceres is focused on incorporating this technology into a range of innovative diagnostic products.
Its lead product is a urine-based Lyme Antigen test that will provide sensitive detection of Lyme disease, at all stages.
Emanuel “Chip” Petricoin, PhD, is one of the co-inventors of the Nanotrap® technology and a co-founder of Ceres.